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Summary 
An overproduction ofproinflammatory cytokines by activated macrophages/monocytes medi- 
ates the injurious sequelae of inflammation, septic  shock, tissue injury, and cachexia. We re- 
cently synthesized a tetravalent gnanylhydrazone compound (CNI-1493) that inhibits cytokine- 
inducible arginine transport and nitric oxide (NO)  production in macrophages, and protects 
mice against lethal endotoxemia and carrageenan-induced inflammation. During these investi- 
gations we noticed that CNI-1493 effectively  prevented lipopolysaccharide (LPS)-induced NO 
production, even when added in concentrations 10-fold less than required to competitively 
inhibit L-arginine uptake, suggesting that the suppressive  effects of this guanylhydrazone com- 
pound might extend to other LPS-induced responses.  Here, we report that CNI-1493  sup- 
pressed the LPS-stimulated production of proinflammatory cytokines (tumor necrosis  factor 
[TNF], interleukins 1[3 and 6,  macrophage inflammatory proteins lcx and 1 [3) from human 
peripheral blood mononuclear cells. Cytokine suppression was specific,  in that CNI-1493 did 
not inhibit either the constitutive synthesis of transforming growth factor [3 or the upregnlation 
of major histocompatibility complex class II by interferon ~/ (IFN-~/).  In contrast to the mac- 
rophage suppressive  actions of dexamethasone, which are overridden in the presence of IFN-% 
CNI-1493  retained its suppressive  effects even in the presence of IFN-% The mechanism of 
cytokine-suppressive action by CNI-1493 was independent of extracellular L-arginine content 
and NO production and is not restricted to induction by LPS. As a selective inhibitor of mac- 
rophage activation that prevents TNF production, this tetravalent guanylhydrazone could be 
useful in the development ofcytokine-suppressive agents for the treatment of diseases mediated 
by overproduction of cytokines. 
p roinflammatory  cytokines,  nitric  oxide  (NO), 1  and 
other macrophage products mediate the  injurious se- 
quelae that define a  spectrum  of diseases including lethal 
septic  shock,  tissue  injury,  cachexia,  hemorrhagic shock, 
vascular leakage syndromes, transplant rejection, rheuma- 
toid arthritis, and other inflammatory states (1--4). This un- 
derstanding led to the development of experimental thera- 
pies based on directly inhibiting cytokines in a number of 
diseases  (e.g.,,  monoclonal anti-TNF antibodies,  IL-1  re- 
1Abbreviations used in this paper: FBS, fetal  bovine serum; GADPH, glycer- 
aldehyde-3-phosphate dehydrogenase; IC50, 50% inhibitory concentra- 
tion; iNOS, inducible  nitric oxide  synthase;  LDH, lactate  dehydrogenase; 
DNMA, NQrnethyl-L-arginine;  MIP-I~x,  rnacrophage  inflammatory  pro- 
tein l~x; MTT, 3-[4, 5-Dimethy/Thiazol-2-yl]-2,  5-dipbenyltetrazolium 
bromide; NO, nitric oxide; TSST-1, toxic shock syndrome  toxin. 
ceptor antagonists, and TNF-receptor fusion proteins)  (5-9). 
More recently, there has been renewed interest in the de- 
velopment of novel therapeutic strategies  to  suppress  the 
production ofproinflammatory cytokines and NO by mono- 
cytes (10-14). The development of effective compounds in 
this regard has provided a better understanding of the biol- 
ogy of the activated macrophage, and indicates that it may 
be feasible to treat cytokine-mediated toxicity by suppress- 
ing the excessive production of cytokines. 
In the course of investigating a strategy to inhibit NO 
production in macrophages without simultaneously inhib- 
iting endothelium-derived relaxing factor activity, we re- 
cendy designed and developed a tetravalent guanylhydra- 
zone  compound  (15). Termed  "CNI-1493,"  N,N'-bis 
[3,5-bis  [l(aminoiminomethyl) hydrazono]ethyl]phenyl]de- 
canediamide tetrahydrochloride (CAS Reg.  No.  164301- 
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kine-inducible  (but not constitutive)  L-arginine uptake  in 
macrophages activated with LPS and IFN-~/(15). Adminis- 
tration of this compound to mice prevented the production 
of NO  in stimulated  resident peritoneal  macrophages, and 
conferred protection against both carrageenan-induced in- 
flammation  and  lethal  endotoxemia  (15).  While  studying 
the  mechanism by which  CNI-1493  inhibited  L-arginine 
transport  in  nonactivated  (quiescent)  macrophages  before 
LPS exposure,  we  discovered that  10-fold less  CNI-1493 
concentrations effectively antagonized the induction of NO 
synthesis in naive cultures (15). These macrophage-suppres- 
sive  activities  at  very  low  concentrations  of CNI-1493 
were  independent  of extracellular  L-arginine,  and  could 
not  be  attributed  to  competitive  inhibition  of L-arginine 
uptake. Since increased arginine uptake and stimulated NO 
production are hallmarks  of the  LPS-induced macrophage 
activation  response  that  also  includes  the  production  of 
proinflammatory cytokines, we reasoned that the suppres- 
sive effects of CNI-1493 might include antagonizing other 
LPS-induced responses, including cytokine synthesis. 
In this study, we report that CNI-1493 effectively sup- 
presses several functional components of the activated mac- 
rophage phenotype, including the induction of pro-inflam- 
matory cytokines,  inducible  nitric  oxide  synthase  (iNOS) 
and L-arginine uptake in LPS-stimulated monocytes/mac- 
rophages. The mechanism ofcytokine suppression by CNI- 
1493 treatment was independent ofextracellular L-arginine 
content  and  NO  production.  CNI-1493  suppressed  the 
production ofproinflammatory cytokines, but not the anti- 
inflammatory cytokine TGF-[3.  Moreover,  CNI-1493 did 
not suppress the upregulation of MHC  class II antigen ex- 
pression  induced  by IFN-~/.  When  administered  to  mice 
receiving lethal  doses  of LPS,  CNI-1493 blocked the  ap- 
pearance of TNF in serum. 
Materials and Methods 
Cell Isolation and Culture.  For studies of murine macrophage- 
like  cells, RAW 264.7 'cells were obtained from The American 
Type Culture Collection (R.ockvitle, MD) and seeded into 6- or 
24-well tissue culture plates  (106 cells/ml RPMI with  10% fetal 
bovine serum  [FBS]) as required  in different  experiments.  For 
studies of human monocytes, buffy coats were obtained by elutri- 
ation from normal individual  donors to the Long Island  Blood 
Bank Services  (Melville,  NY). PBMC were isolated  by density 
gradient centrifugation through Ficoll (Ficoll-Paque  |  PLUS, en- 
dotoxin tested;  Pharmacia,  Piscataway,  NJ); typically  one prepa- 
ration yielded 200  ￿  106 adherent cells. These were cultured in 
24-well plates (2 ￿  106 cells/ml R.PMI with 10% normal human 
serum).  Nonadherent cells were removed by changing the media 
after 18 h. 
Cytokine Induction.  Working stock LPS  (Eschetichia coli 0111: 
B4; Sigma  Chemical Co., St. Louis,  MO) solutions  (100 I~g/rnl 
in PBS, pH 7.4) were sonicated for 10 min before use. For induc- 
tion of monocytes, LPS was diluted in individual wells to a final 
concentration of 100 ng/ml.  IFN-~/  (25 U/ml)  was coadrninis- 
tered with LPS; recombinant m-IFN-~/ (Genzyme Corp.; Cam- 
bridge, MA) was used for induction of RAW cells, recombinant 
h-IFN-~/  (Boehringer  Mannheim,  Mannheim,  Germany)  was 
used  for induction  of human  PBMC.  In independent  experi- 
ments, we found that the simultaneous  addition of these concen- 
t'rations of LPS and IFN-~/were maximally effective in stimulat- 
ing the release of TNF (data not shown). Toxic shock syndrome 
toxin  (TSST-I;  Toxin Technology; Sarasota,  FL)  was  used for 
TNF induction in RAW cells at a final concentration of 2 I~g/ml. 
Cytokine Assays.  TNF  concentrations  in murine  serum and 
in the supematants of stimulated  RAW cells were determined by 
ELISA (Genzyme Corp.) performed in 96-well microtiter plates 
(minimum detectable  concentration [MDC], 10 pg/ml). Human 
cytokines were measured by other commercially available ELISA 
kits according to the package instructions.  MDCs were the fol- 
lowing: TNF  (R&D Systems, Inc., Minneapolis,  MN),  4.4 pg/ 
ml; IL-113 (R&D Systems, Inc.), 0.3 pg/ml; IL-6 (R.&D Systems, 
Inc.), 0.7 pg/ml; and TGF-13 (Genzyme Corp.), 50 pg/ml. Mac- 
rophage inflammatory protein  lot  (MIP-lot) and  MIP-II3 con- 
centrations were determined by an in-house ELISA (MDC,  10 
pg/ml). Where indicated in some experiments,  TNF (murine and 
human) bioactivity was assayed by a standard L929 cell cytotoxic- 
ity bioassay;  specificity  was verified  by addition  of neutralizing 
anti-TNF antibodies.  Separate experiments (not shown) revealed 
that CNI-1493 did not interfere with the L929 bioassay, as iden- 
tical standard  curves  (prepared  using rmTNF and rhTNF) were 
obtained in the absence and presence of added CNI-1493. 
CNI-1493 Additions.  CNI-1493  was  synthesized  and  puri- 
fied as previously described  (15). The purity was >99% as esti- 
mated  by  melting  point,  nuclear  magnetic  resonance,  elution 
from HPLC, and elemental  analysis. Working stock solutions  (i 
raM) were prepared fresh in sterile-filtered  deionized water. For 
individual  experiments,  aliquots of the stock solution were added 
directly into individual  tissue culture wells, yielding the final con- 
centrations indicated.  In all experiments,  control wells received 
an  equal  volume  of sterile  deionized  water  (vehicle)  only.  In 
agreement with previous results,  neither CNI-1493 nor vehicle 
in the concentrations used has any significant effect on cell viabil- 
ity as assessed by morphology, conversion of 3-[4,  5-Dimethy/ 
Thiazol-2-yl]-2, 5-diphenyltetrazolium bromide  (MTT)  to for- 
mazan,  or the release  of lactate  dehydrogenase (LDH) into the 
media  as  tested  for RAW 267.4  cells, murine  fibroblast  L929 
cells, and human PBMC. 
RNA Isolation and RNase Protection Analyses.  Total  cytoplas- 
mic RNA was isolated from RAW 264.7 cells (typically from 10- 
cm tissue culture plates) at various time points after LPS/IFN-~/ 
stimulation  (100  ng/m/ LPS and 25 U/rnl  IFN-~) essentially as 
described (16) except that 200 mM ribonucleoside-vanadyl com- 
plex (10 I.d, Sigma Chemical Co.) was added to the ceils before 
lysis with detergent (300 I.d, 0.5% NP-40, 0.14 M NaC1, and 1.5 
m/vl Tris,  pH 8.6).  mR.NAs for mTNF and murine glyceralde- 
hyde-3-phosphate  dehydrogenase  (GADPH)  were  detected  by 
R.Nase  protection analysis performed as described  (16). Briefly, 
antisense  mRNAs were  transcribed  in vitro  in the  presence  of 
[32p]CTP  from vectors containing cDNA templates  coding for 
the above cytokines cloned behind the bacterial  promoters T3, 
T7, or SP6.  Radiolabeled antisense  mR.NAs were then purified 
by electrophoresis  through a urea polyacrylamide gel and eluted 
in 0.1%  SDS,  0.3  M  sodium acetate,  pH  5.0,  and precipitated 
with ethanol.  Hybridization of antisense  probe to  1 I~g of total 
cytoplasmic  RNA was  in 80% forrnamide  at  45~  for 8-12  h. 
Hybridization mixes were then digested with 40 ~g/rnl R.Nase A 
and 200 U/ml ILNase T1 for 45 min at 30~  followed by pro- 
teinase K digestion.  The digested  P,.NAs were separated  by elec- 
trophoresis  on a sequencing-type urea gel. Murine TNF mRNA 
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Figure 1.  (A) Dose--response study of the inhibitory ef- 
fects of CNI-1493  on immunodetectable TNF produced 
by LPS plus IFN-~/-stimulated RAW 264.7 cells. Cultured 
cells were pretreated  with CNI-1493 for 1 h, stimulated 
with LPS plus IFN-% and media harvested 4 h later as de- 
scribed in Materials and Methods.  TNF levels in the con- 
ditioned media  were determined by ELISA. Data shown 
are mean +  SE, each in triplicate. (B) Effect of CNI-1493 
on RNA synthesis in LPS-stimulated  RAW 264.7  cells. 
Cultured cells were pretreated  with 10 I~M CNI-1493 for 
1 h, then stimulated with LPS. 4 h later, the incorporation 
of [14C]uridine into RYqA was measured by adding the ra- 
diolabeled nucleotide for a 3-h period. The RNA fraction 
was then isolated, as described in Materials and Methods, 
and the radioactivity determined in a Beckman scintillation 
counter. Data  shown are mean +  SE, each in triplicate. 
(C) Effect of CNI-1493 on cellular respiration  (MTT as- 
say) in RAW 264.7 cells. RAW cells were pretreated with 
CNI-1493 for 1 h, stimulated with LPS plus IFN-% and 
4 h  later,  an MTT-based assay of cellular respiration  was 
performed as previously  described  (27). Data  shown are 
mean +  SE, each in triplicate. 
was  detected with a  212-nucleotide RNA  probe derived from 
the EcoRI linearized template plasmid pGEM3Zf + mTNF; this 
probe is complementary to the native 5'-end of  the transcript and 
yields a protected fragment of 169  nucleotides. Mouse GADPH 
mRNA was detected with a 135-nucleotide RNA probe derived 
from a linearized plasmid purchased from GIBCO BRL (Gaith- 
ersburg, MD). This probe is complementary to an internal region 
of human GADPH and yields a protected fragment of 95  nucle- 
otides.  However, because human  and  mouse  GADPH  are  not 
completely identical, incomplete hybridization leads to the gener- 
929  Bianchi et al. ation of a shorter protected fragment of about 50 nucleotides as 
measured by gel electrophoresis. 
Construction ofPlasmids.  All  plasmids contained  a  bacterio- 
phage promoter to  direct in  vitro  tkNA  synthesis  of antisense 
RNA used for RNase protection analysis, pGEM3Zf +  TNF was 
constructed  by  cloning  a  RT-PCR  product  with  EcoRI  and 
BamHI  ends  into  the  multiple  cloning  site of  pGEM3Zf+ 
(Promega Corp., Madison,  WI). The PCR product (185 bp) was 
obtained using total cytoplasmic RNA fi:om LPS-stimulated RAW 
264.7  cells as  template  and  the  primers  5'-GGGGAATTCA- 
GAAGGCTCCCTC-3'  and  5'-GGGATCCGGTGTCTTTTC- 
TGG-3'. A  plasmid coding for GADPH was  obtained  linearized 
from GIBCO BRL. 
Determination of RNA Synthesis.  RAW 264.7  cells (106 cells/ 
ml) were allowed to adhere in petri  dishes  (10 ml)  for 18 h, in 
tLPMI with 10% FBS. The media were then replaced with media 
containing either CNI-1493 in the concentrations indicated,  or 
actinomycin D  (50 I~g/ml)  as a positive  control. After 1 h, the 
cells were stimulated  with LPS  (100  ng/ml) and 4 h later,  they 
were  washed  twice  with  PBS  and  exposed  to  [14C]uridine  (1 
p~Ci/plate, specific activity 521 mCi/mmol; NEN-DuPont, Bos- 
ton, MA) for 3 h. The RNA was extracted with tkNAzol (RNA- 
zol B; TEL-TEST, Inc., Friendswood, TX) and the radioactivity 
incorporated into RNA was measured in a scintillation  counter 
(model LS 7800; Beckman lnsts.,  Fullerton,  CA). 
Determination of Protein Synthesis.  RAW 264.7  cells were  al- 
lowed to adhere in 6-well plates  (2  ￿  106 cells/ml R.PMI with 
10% FBS) for 18 h, washed with methionine-free DMEM,  and 
then incubated for 1 h in methionine-free DMEM with 10% dia- 
lyzed  FBS.  [3SS]Methionine  (8  mCi/ml,  NEN-DuPont)  was 
added to individual  wells  (50 p~Ci/well)  simultaneously  with or 
without stimulating  agents  (LPS and IFN-',/). CNI-1493 (5 IxM) 
was added 1 h before the stimulating  agents where indicated.  At 
the indicated time points after addition of the stimulating  agents, 
superuatants  were collected and radiolabeled  cells washed in ice- 
cold PBS, then lysed in RIPA buffer (150 mM NaC1, 1% NP-40, 
0.5%  deoxychohc acid,  0.1%  SDS,  50 mM  Tris-HC1,  pH  7.5, 
and 2 mM EDTA). Intracellular  proteins were precipitated by ad- 
dition of TCA, the pellets collected by centrifugation, and radio- 
active counts determined. 
Results 
Effects of CNI- 1493 on the Production of TNF.  When acti- 
vated by exposure  to LPS and IFN-% cells  of the macro- 
phage/monocyte  lineage  produce  copious  amounts  of 
TNF.  We  initially  examined  the  direct  effects  of CNI- 
1493  on TNF production in activated cells  of the  murine 
macrophage-hke  cell  line  RAW  264.7.  CNI-1493  effec- 
tively inhibited LPS and IFN-~/--stimulated RAW  cell pro- 
duction  of TNF  as  measured  by ELISA (Fig.  1 A).  The 
50% inhibitory concentration (IC50) was ~500 riM;  >90% 
suppression  occurred with  concentrations  -----1 IXM. West- 
ern  blotting  of concentrated  supernatants  obtained  from 
LPS and IFN-~/--stimulated RAW cells indicated that CNI- 
1493 inhibited  the production of immunodetectable  TNF 
(not shown). We also measured TNF bioactivity in a stan- 
dard  L929  cell  cytotoxicity assay,  and  observed  a  similar 
ICs0 for CNI-1493 inhibition ofbioactive TNF (500 riM). 
Previous observations demonstrated that TNF transcrip- 
tion  and  translation  are  upregulated  within  minutes  after 
LPS  stimulation  (17,  18).  We  performed  a  time  course 
study to assess the effects of CNI-1493 added to monocytes 
at  different  stages  of LPS  and  IFN-~/-induced  activation. 
TNF protein production was completely suppressed when 
CNI-1493 was added to quiescent monocytes before stim- 
ulation with LPS and IFN-~/(Table 1), but when added to 
monocytes just before or after their activation by LPS and 
IFN-%  CNI-1493  was  less  effective  in  suppressing  TNF 
production.  This loss of cytokine-suppressive activity sug- 
gests that  CNI-1493 inhibits  macrophage  activation  at  an 
early stage in the intracellular signaling pathway. 
Additional  experiments  were  performed  to  address 
whether  the  cytokine-suppressive  effects  of  CNI-1493 
were reversible.  Cells were pretreated with CNI-1493 (2.5 
p,M)  for  1  h;  CNI-1493  was  then  removed by culturing 
under  fresh  media  devoid  of CNI-1493  for 30  rain,  and 
LPS and IFN-~/were added. We observed no difference in 
TNF produced over the subsequent 2 h in controls (25 +_  1 
ng  TNF/106  cells)  or  in  CNI-1493-treated  and  washed 
cells  (24  +  2  ng TNF/106  cells).  Thus,  the  cytokine-sup- 
pressive effects of CNI-1493 are readily reversible, suggest- 
ing  that  monocytes  exposed  to  this  guanylhydrazone  are 
not permanently  impaired  from future  immunological re- 
sponsiveness. 
We  addressed  the possibility that  CNI-1493 exerted  its 
effects  by inhibiting  RNA  synthesis.  The  1LNA synthesis 
inhibitor  actinomycin D  (50  p,g/ml)  was  used  as positive 
control.  As  shown  in  Fig.  1  B,  we  did  not  observe  any 
change in the incorporation of [14C]-uridine into tkNA in 
the  cells  treated  with  10  p~M  of  CNI-1493  and  LPS 
(25,290  +--  97  cpm)  vs.  the  controls  receiving  LPS  alone 
(25,370  +  70 cpm). Thus, the cytokine-suppressive actions 
of CNI-1493 are not the result of nonspecific inhibition of 
de novo transcription.  Addition of pharmacologic quanti- 
ties of CNI-1493 to LPS plus IFN-~/-stimulated RAW  cell 
cultures was not toxic, as assessed  by LDH release into the 
media,  MTT  assay  (as shown in  Fig.  1  C),  cell counting, 
and cell morphology by light microscopic inspection. 
Table I.  Kinetic Study of the Inhibitory Effects of CNl-1493 on 
TNF Production in LPS and IFN-y--stimulated  RAW 264.7 Cells 
Time CNI-  1493 added  TNF (ng/106 cells) 
rain 
--60*  <0.4 
--30  <0.4 
--5  17 +  1 
+5  16 +  3 
+30  16 +  1 
Control (no CNI-1493)  25  +  1 
*LPS plus IFN--V were added at time zero and CNI-1493 (2.5 p.M) 
added at the relative time indicated. 
TNF in supernatants collected 2 h after LPS and IFN-~/ were assayed 
by ELISA. Data  are  mean  +--  SE  from  three  experiments, each in 
triplicate. 
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produced in vivo occupies a pivotal role in the mediation of 
endotoxin lethality (5, 19), we next assessed whether CNI- 
1493  inhibited peak serum TNF levels in mice given a le- 
thal  dose  of LPS.  CNI-1493  attenuated  the  LPS-induced 
increases in serum TNF in a dose-dependent  manner  (Fig. 
2),  suggesting  that the  previously  described  protective  ef- 
fects of CNI-1493  against LPS lethality in mice (15)  are in 
part accounted  for by inhibition  of the  systemic TNF  re- 
sponse. This effective suppression of TNF by CNI-1493  in 
an  animal  model  of acute  cytokine  overproduction  indi- 
cates that it may be feasible to prevent cytokine toxicity in 
vivo with this agent. 
CNI-1493 Inhibits Expression of iNOS.  The observation 
that  CNI-1493  suppressed  TNF  production  both  in  cul- 
tured  monocytes  and  in  vivo  prompted  us  to  investigate 
whether it inhibited  the induction  of iNOS,  another char- 
acteristic element of the murine macrophage activation re- 
sponse to LPS and IFN-~/(13,  20). We previously reported 
that  CNI-1493  is  not  a  direct  inhibitor  of iNOS  activity 
when  added  to  enzyme  preparations  (15),  but  in  the 
present experiments we assessed whether pretreatment with 
CNI-1493  inhibited  the  induction  of iNOS  activity.  Ac- 
cordingly,  we measured iNOS activity in cell lysates of LPS 
plus  IFN-~/--activated  RAW  cells  pretreated  with  CNI- 
1493  (Table  2).  In  agreement  with  others  (13,  20),  LPS 
plus IFN-~/in control cultures induced  a robust increase in 
iNOS  activity.  CNI-1493  effectively inhibited  the  induc- 
tion ofiNOS. 
Effects of CNI- 1493 Are Specific.  We  next  investigated 
the  possibility  that  the  suppressive  effects  of CNI-1493 
were secondary to a generalized suppression of protein syn- 
thesis.  In a protein synthesis  assay, CNI-1493  (5  IxM) did 
not significantly inhibit the  total incorporation  of [35S]me- 
thionine  into  TCA-precipitable  proteins  from  lysates  of 
RAW  264.7  cells that had been  stimulated  with  LPS plus 
IFN-~/during a 4-h pulse of [3SS]methionine  (controls,  1.5 
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CNI-1493  inhibits serum TNF levels in endotoxemic mice. 
BALB/c mice received CNI-1493 by intraperitoneal injection at the dose 
indicated, and 90 min later received LPS (E. coli  0111 :B4) by intraperito- 
neal injection (13.75 mg/kg). After 90 rain, blood was collected by car- 
diac puncture, and serum TNF determined by ELISA. Data shown are 
mean +  SE, n =  6-8 animals per group shown. 
Table 2.  CNI- 1493 Prevents the Induction of iNOS Activity 
Total NOS activity 
[CNI-1493]  LPS/IFN-y  (pmol/mg/min) 
0  --  2.8 +  0.14 
0  +  28.2 +  1.31 
1  +  18.2  +  0.71" 
5  +  4.1  +  0.17" 
RAW 264.7 cells were plated and induced with LPS plus IFN-"/as de- 
scribed in Materials and Methods. CNI-1493 was added 1 h before in- 
ducing agents. Cell lysates were prepared 8 h after activation and total 
NOS  activity was  determined  as previously  described  (9). Data  are 
mean +  SE of three different experiments, each in triplicatae. 
* <0.05 vs. LPS/IFN-"/-induced cells without CNI-1493. 
￿  105  cpm,  vs.  CNI-1493,  1.3  ￿  10 s  cpm).  Cyclohexi- 
mide  (60  p,g/ml),  used  as  a  positive  control,  significantly 
inhibited  incorporation  of radioactivity  (8.3  ￿  102  cpm). 
When  lysate  proteins  were  separated  by  SDS-PAGE  and 
visualized by autoradiography, no differences were noted in 
either the  pattern  or  the  quantity  of labeled proteins  syn- 
thesized (not shown). 
TNF mRNA Levels.  The mechanism of action of CNI- 
1493  was studied  by testing its abihty  to  inhibit  LPS plus 
IFN-~/-stimulated TNF mRNA  levels.  In agreement with 
previous  observations,  TNF  mRNA  levels determined  by 
RNase  protection  analysis were  increased  in RAW  264.7 
cell cultures after addition of LPS plus IFN-~/; levels peaked 
2  h  after exposure to stimulating  agents  (17,  18).  Pretreat- 
ment  with  CNI-1493  depressed  peak  steady-state  TNF 
mRNA  levels in a dose-independent  manner  (Fig.  3). We 
observed  significant  suppression  of  TNF  mRNA  levels 
when  CNI-1493  was  present  in  concentrations  >1  I~M, 
indicating  that at these  concentrations  the agent either in- 
hibits  transcription  or  accelerates  degradation  of  TNF 
mRNA.  As noted above, we observed that CNI-1493  in- 
hibited 50% of TNF protein with  <  1 I~M concentrations, 
suggesting that CNI-1493  independently  suppressed trans- 
lational  or  posttranslational  processing  steps  in  TNF  bio- 
synthesis. 
Inhibitory  Effects of  CNI-1493  Are  Independent of NO. 
CNI-1493  is an inhibitor  of NO  production  by activated 
murine  monocytes  (15),  and NO  has previously been  im- 
plicated in the  signaling pathway leading  to TNF  produc- 
tion  (21).  Thus,  inhibition  of NO  production  may be one 
explanation  for  the  cytokine-suppressive  effects  of CNI- 
1493.  We  addressed  this  possibility by measuring the  pro- 
duction  of TNF  and  NO  in RAW  cells  treated  for 24  h 
with LPS plus IFN-~ and pretreated with either CNI-1493 
or a competitive inhibitor  of NOS,  NQmethyl-L-arginine 
(L-NMA)  (Fig.  4).  A  concentration  of CNI-1493  (5  p,M) 
that resulted  in a  70% suppression  of NO  production  also 
resulted  in  >95%  suppression  of TNF  production.  This 
differed significantly from the results observed with L-NMA, 
931  Bianchi et al. Figure 3.  Expression  of TNF mRNA in LPS 
and  IFN-"/-stimulated RAW cells. RAW 264.7 
cells were exposed  to  CNI-1493  for 1 h  at the 
concentrations  shown, then stimulated  with LPS 
and IFN-~/for 2 h. Total RNA was isolated and 
tkNase protection analysis performed as described 
in  Materials  and  Methods.  Note  that  TNF 
rnRNA levels are maintained  even though TNF 
protein is inhibited  by 0.5-1  p~M concentrations 
of CNI- 1493. 
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Figure 4.  Inhibition of NO does not mediate  decreased TNF produc- 
tion in LPS plus IFN-~-stimulated RAW cells. RAW 264.7  cells were 
exposed to either CNI-1493 (circles)  or L-NMA (triangles)  in the concen- 
trations shown  for 1 h, and then stimulated with LPS plus IFN-~/as de- 
scribed in Materials and  Methods.  After 24-h culture,  media  were har- 
vested for determination  of TNF by ELISA (A), and nitrites (B) using the 
Greiss reagent  (20). Data shown are mean -+ SE, each in triplicate. The 
absolute value for nitrite production in absence of CNl-1493 was 51  +  4 
nmol/24 h per 106 stimulated cells. 
for which an L-NMA  concentration  (1  mM)  resulting in a 
60% suppression  of NO  did not suppress  TNF  production 
from  control  values.  This  suggests  that  the  cytokine-sup- 
pressive  effects of CNI-1493  do  not  depend  upon  inhibi- 
tion of NO. 
Inhibitory  Effects of CNI-1493  Are Not Restricted to Induc- 
tion by LPS.  To  address  the  possibility  that  CNI-1493 
acts  by inhibiting an  early  step  in LPS  signaling,  we  mea- 
sured  the  effect  of this  agent  on  TNF  production  from 
macrophage  cultures  activated with an independent  stimu- 
lus,  toxic  shock  syndrome  toxin  (TSST-1).  As  shown  in 
Fig. 5,  CNI-1493  suppressed  TNF  production in TSST-1- 
treated  cells, giving evidence that  the cytokine responsive- 
inhibiting  activity  of CNI-1493  is  not  restricted  to  LPS- 
induced macrophage  activation signals. 
Effects of CNI- 1493 on Human Monocytes.  Because of the 
potential therapeutic implications for an experimental agent 
that suppresses production  of proinflammatory cytokines in 
monocytes  and  in vivo, the  cytokine-suppressive  effects of 
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Figure  5.  Dose-response  study of the inhibitory  effects of CNI-1493 
on  immunodetectable  TNF  produced  by  TSST-1--stimuLated  PAW 
264.7  cells. Cultured cells were pretreated  with CNI-1493  at the indi- 
cated doses for 1 h, then stimulated with TSST-1 (2 Wg/rnl) for 15 h. Su- 
pernatants  were collected and analyzed for TNF by ELISA. Data shown 
are mean +  SE, in triplicate. 
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cytes. As shown in Fig. 6,  CNI-1493  was a potent and se- 
lective inhibitor of proinflammatory cytokine production 
by human monocytes. It was ,',d0-fold more potent in pre- 
venting  TNF  and  IL-1  production  in  human  monocytes 
(with an estimated ICs0 of 30-70 nM)  as compared to the 
murine  RAW  264.7  cells (ICs0  ,  500-750  riM).  The  esti- 
mated IC50 for CNI-1493 in preventing the production of 
other proinflammatory cytokines  (MIP-lct, MIP-I[3,  and 
IL-6) by human  PBMC  was  also in the nanomolar range 
(ICs0, 125-175  riM). In separate experiments, we observed 
nearly identical dose--response  curves when human mono- 
cytes were coinduced with rhlFN-'y (25  U/ml) plus LPS 
(100 ng/ml) (data not shown). Thus, the inhibitory actions 
of CNI-1493 on proinflammatory cytokine production are 
not overridden by IFN-3~. 
Specificity  of  CNI-1493's  effects  on  monocytes  was 
evaluated by assay for the production  of TGF-13  and  the 
expression of MHC  class II antigens. Even high concentra- 
tions  of CNI-1493  (2.5  IxM)  failed  to  inhibit  the  con- 
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Figure 6.  CNI-1493  inhibits proinflammatory cytokine production  in human monocytes. Human  PBMC  were isolated, allowed to adhere, and 
washed as described in Materials and Methods. Cells were exposed to CNI-1493 at the concentrations indicated for 1 h, stimulated with LPS (100 ng/ 
ml), media harvested at 4 h, and cytokine levels measured by ELISA. Data shown are mean + SE, n = 6. A, TNF, B, IL-1 IL-II3; C, MIP-loL; D, MIP- 
118; E, IL-6; and F, TGF-13. 
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Figure 7.  CNI-1493 does not inhibit IFN-',/-mediated upregulation of 
MHC class II expression on human monocytes. Human PBMC were dis- 
persed by treatment with cold 0.2% ethylene diamine tetraacetic acid in 
PBS, pH 7.2. Cell suspensions were washed twice in PBS containing 1% 
BSA and 0.1% sodium azide (FACS  |  media; Becton Dickinson & Co., 
Mountain View, CA). The cells were then resuspended in 25 l.tl of di- 
luted FITC-conjugated  anti-HLA-DP,  or an isotype standard antibody 
(PharMingen, San Diego, CA) and incubated on ice for 20 rain. The cells 
were washed twice and at least 10,000 cells analyzed on a FACScan  |  in- 
strument (Becton Dickinson & Co.). Cells shown in A were exposed to 
IFN-y dose for 4 h; cells shown in B were exposed to CNI-1493  (2.5 
tiM) plus IFN-~/(25 U/ml) for 4 h. 
stitutive  production  of the  "anti-inflammatory  cytokine" 
TGF-[3  by adherent  human  monocytes  (Fig.  6  F).  Addi- 
tional  evidence  of selectivity  is  given  by  the  observation 
that CNI-1493  did not inhibit IFN-y-rnediated  upregula- 
tion of MHC  class II expression on human monocytes (Fig. 
7). Since CNI-1493 was originally designed as a direct, com- 
petitive inhibitor of cytokine-inducible  L-arginine transport, 
we  also  investigated  the  possibility that  the  cytokine-sup- 
pressive  mechanism  in  human  monocytes  was  dependent 
upon extracellular L-arginine availability. As shown in Ta- 
ble 3, we observed no relationship between L-arginine me- 
dia concentrations and the inhibition  ofLPS-induced TNF 
responses  in  human  rnonocytes,  suggesting  that  the  cyto- 
kine-suppresive effects did not depend upon L-argimne avail- 
ability.  In  separate  studies  using  a  related  but  structurally 
distract trivalent guanylhydrazone, 2,2'-[5-[[[[[4-[1-[2-(ammo- 
iminomethyl) -hydrazono] ethyl] phenyl] amino] carbonyl] ami- 
no]-1,3-phenylene] diethylidyne]-bis(hydrazinecarboximida- 
mide)  trihydrochloride  (CNI-993),  we  observed  similar 
cytokine-suppressive  activity  (not  shown),  suggesting  that 
other  members  of this  structural  class  of guanylhydrazone 
compounds also possess cytokine-suppressive activity. 
Discussion 
The tetravalent guanylhydrazone CNI-1493  was initially 
developed as a competitive inhibitor of cytokine-inducible 
L-arginine transport in activated monocytes,  but we found 
it to be more effective in preventing the induction  of NO 
production  in  quiescent  monocytes  (15).  The  present  re- 
sults now reveal that compounds  of this structural  class  ef- 
fectively inhibit  the  production  of TNF  and  other proin- 
flammatory  cytokines  by  human  rnonocytes  (Table  4). 
These cytokine-suppressive  effects are not mediated by in- 
hibition  of NO  or L-arginine  transport  or by generalized 
suppression  of protein  or RNA  synthesis,  and do  not lead 
to inhibition  of either TGF-[3  release  or IFN-~/-mediated 
upregulation of MHC  class II expression. 
The  molecular  target  of these  guanylhydrazone  com- 
pounds  in  activated monocytes  has yet to be  determined, 
but  the  present  studies  suggest important  differences  from 
another  class  of anti-inflammatory  agents  that  inhibit  cy- 
tokine  production.  Glucocorticoid  hormones  have  been 
studied  extensively  for  their  cytokine-suppressive  effects, 
which  have been linked  to  the  anti-inflammatory  proper- 
ties of these steroids. 
When added to monocytes before LPS stimulation,  dex- 
amethasone is an inhibitor both ofTNF  gene transcription 
(with  resultant  suppression  of rnRNA  accumulation),  and 
ofmRNA  translation  (together leading to a >95% suppres- 
sion  of TNF  protein  synthesis)  (18,  22).  IFN-~/ can  com- 
pletely override the cytokine-suppressive effects of the gluco- 
corticoids,  enabling LPS plus IFN-y-stimulated monocytes 
to produce robust quantities of TNF despite glucocorticoid 
treatment (23). In contrast to the glucocorticoids,  CNI-1493 
was  not  overridden  by  IFN-~/  treatment,  because  CNI- 
1493  effectively inhibited  cytokine production by LPS and 
IFN-~-costimulated  murine  and  human  monocytes.  This 
may be particularly relevant to anti-inflammatory strategies 
in  vivo,  since  IFN-~/  is  nearly  ubiquitous  in  acute  and 
chronic  inflammatory states,  and  serves to limit the  utility 
of glucocorticoids  in  clinical  settings when  effective cyto- 
kine-suppressive  compounds  are  most  critically  needed. 
Additional  evidence  for  the  divergent  actions  of  dexa- 
rnethasone and CNI-1493 in activated monocytes is found 
in the  observation  that CNI-1493  prevented induction  of 
both L-arginine uptake and iNOS, whereas dexamethasone 
suppresses  only  iNOS  and  leaves the  induction  of L-argi- 
nine transporters unaffected (13). 
The  present  findings  give  evidence  that  CNI-1493  in- 
hibits  TNF  production  at  the  translational  or  posttransla- 
934  Tetravalent Guanylhydrazone Suppresses Proinflammatory Cytokines Table 3.  The Cytokine-suppressive Effects of CNI- 1493 Do Not 
Respond to Increasing L-arginine Availability 
TNF (IU/ml) 
[CNI-1493]  [CNI-1493]  [CNI-1493] 
[L-arginine]  =  0  =  1  =  5 
p,M  p,M  I.*M 
10  543  •  31  17 •  3  <0.3 
100  543 +  22  23 +  2  <0.3 
1,000  743 •  19  23 +  3  <0.3 
Table 4.  LPS-induced Monocyte Responses Inhibited by 
CNI-1493 
L-arginine transport 
NO production 
TNF 
IL-liB 
IL-6 
MIP-lcx 
MIP-1[3 
Human PBMC were prepared as described in Materials and Methods 
and incubated in defined media (tLPMI) containing L-arginine in the 
concentrations shown. CNI-1493 was added 1 h before LPS, and con- 
ditioned media were harvested 4 h after activation. TNF bioactivity was 
determined by L929 bioassay. (Note: the physiological range of serum 
L-arginine concentration is 100-150 t~M.) Data are mean + SE of three 
different experiments, each in triplicate. 
tional level,  because  TNF  protein  synthesis  is  reduced by 
lesser  concentrations  of CNI-1493  than  are  required  to 
suppress steady-state m_tLNA levels. Although the molecu- 
lar target(s)  of CNI-1493 remains  undefined,  it will be of 
interest  to  measure  TNF  mR.NA  stability,  transcription 
rates,  and  the  activity  of LPS-induced  kinases  in  CNI- 
1493-treated monocytes. These studies  might enable  a di- 
rect comparison between the CNI-1493 mechanism of ac- 
tion, and that of other TNF inhibitors.  For instance, Lee et 
al.  (12)  recently showed that pyridinyl imidazoles that tar- 
get  mitogen-activated  kinase  inhibit  TNF  production  in 
human  monocytes,  primarily  by blocking translational  or 
posttranslational  processing.  Another  strategy  to  inhibit 
TNF  has been  proposed by Moreira  et  al.  (11),  who  re- 
ported that thalidomide is a selective inhibitor of TNF pro- 
duction, which acts primarily by enhancing the degradation 
ofTNF  mtLNA. Because CNI-1493 inhibits a spectrum of 
LPS-induced activation responses  (Table 4), it was reason- 
able to hypothesize that its principle site of action could be 
at a proximal stage in LPS signaling.  The result that CNI- 
1493  inhibited  the  TSST-l-induced  TNF  response  sug- 
gests  that  the  target  is  not  restricted  to  the  LPS  signaling 
pathway  in  macrophages.  Both  LPS  and  TSST-1  induce 
the activation of mitogen-activated protein kinases and nu- 
clear factor KB  (24),  which stimulate  macrophage  activa- 
tion and translational regulation ofcytokine production. 
A  relative  overproduction  of TNF  occurs  in  patients 
with septic shock syndrome, HIV infection, meningitis,  al- 
lograft rejection, hemorrhagic shock, and other inflamma- 
tory states  (4).  Although excessive TNF levels in critically 
ill  patients  may be lethal,  lesser quantities  of TNF  occupy 
an important  role in host defense,  especially,  for instance, 
against intracellular pathogens (25, 26).  Therefore, an ideal 
cytokine-suppressive  agent  would  act reversibly,  in  order 
to enable the monocytes to recover their ability to mount a 
protective TNF response after the drug is cleared.  In addi- 
tion,  an ideal cytokine-suppressive agent would not inter- 
fere with expression of MHC  class II molecules on the cell 
surface,  in  order  to  maintain  immunological  effectiveness 
in  host  defense.  Our studies  now show  that  a  tetravalent 
guanylhydrazone selectively  and  reversibly inhibits  proin- 
flammatory  cytokine  synthesis  in  vitro,  and  attenuates  in 
vivo TNF production and endotoxemic death. It is possible 
that  guanylhydrazone  compounds  of this  structural  class 
may be useful in the  treatment  of diseases mediated by an 
overproduction of pro-inflammatory cytokines. Studies are 
in progress to identify the molecular target of CNI-1493 in 
antagonizing the activation ofmacrophages. It is hoped that 
these will provide additional insight into the signals regulat- 
ing the macrophage activation phenotype. 
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